Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014, Article ID 857148, 9 pages
http://dx.doi.org/10.1155/2014/857148
Clinical Study

A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

1Department of Ophthalmology, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, West Midlands CV2 2DX, UK
2Institute of Eye Surgery and Macular Pigment Research Group, Whitfield Eye Clinic, Waterford, Ireland
3Department of Ophthalmology, Faculty Hospital, Vojtecha Spanyola 43, 012 07 Zilina, Slovakia
4Hospital Provincial Divino Valles, Avenida Islas Baleares 1, 09006 Burgos, Spain
5Oogcentrum Oostende, Koninginnelaan 54, 8400 Oostende, Belgium
6Novartis Pharma AG, CH-4002 Basel, Switzerland

Received 23 December 2013; Revised 7 March 2014; Accepted 12 March 2014; Published 28 April 2014

Academic Editor: Timothy Y. Lai

Copyright © 2014 Sergio Pagliarini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Sergio Pagliarini, Stephen Beatty, Blandina Lipkova, et al., “A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study,” Journal of Ophthalmology, vol. 2014, Article ID 857148, 9 pages, 2014. https://doi.org/10.1155/2014/857148.